Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Compared with the lowest quintile of midlife physical activity, the top two quintiles were associated with 40% lower ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main ​goal in late-stage trials ...